WO2006037344A1 - Compositions pharmaceutiques comprenant du fenofibrate et de l'atorvastatine - Google Patents

Compositions pharmaceutiques comprenant du fenofibrate et de l'atorvastatine

Info

Publication number
WO2006037344A1
WO2006037344A1 PCT/DK2005/050001 DK2005050001W WO2006037344A1 WO 2006037344 A1 WO2006037344 A1 WO 2006037344A1 DK 2005050001 W DK2005050001 W DK 2005050001W WO 2006037344 A1 WO2006037344 A1 WO 2006037344A1
Authority
WO
WIPO (PCT)
Prior art keywords
fenofibrate
atorvastatin
dosage form
vehicle
pharmaceutical composition
Prior art date
Application number
PCT/DK2005/050001
Other languages
English (en)
Inventor
Per Holm
Tomas Norling
Original Assignee
Lifecycle Pharma A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lifecycle Pharma A/S filed Critical Lifecycle Pharma A/S
Priority to CA002582403A priority Critical patent/CA2582403A1/fr
Priority to EP05789004A priority patent/EP1804769A1/fr
Publication of WO2006037344A1 publication Critical patent/WO2006037344A1/fr
Priority to US11/449,918 priority patent/US9173847B2/en
Priority to US11/456,566 priority patent/US20070014846A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Abstract

L'invention concerne des compositions pharmaceutiques sous forme particulaire ou en formes galéniques solides, qui comprennent une combinaison de fénofibrate et d'atorvastatine, un inhibiteur de la HMG-CoA réductase, ou d'un sel pharmaceutiquement actif de celle-ci. L'administration par voie orale de ces compositions permet d'obtenir une valeur AUC0-24 relative (AUCacide fibrique/AUCatorvastatine) comprise entre environ 250 et environ 10000. La fabrication de ces compositions solides ne nécessite pas d'adjonction d'eau ni de support aqueux. L'atorvastatine est éventuellement fournie comme formulation à libération contrôlée ou retard pour assurer un effet prolongé de réduction des LDL à une dose réduite, et le fénofibrate est fourni dans une formulation présentant une biodisponibilité accrue et un effet réduit sur la prise alimentaire.
PCT/DK2005/050001 2003-10-10 2005-10-03 Compositions pharmaceutiques comprenant du fenofibrate et de l'atorvastatine WO2006037344A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002582403A CA2582403A1 (fr) 2004-10-01 2005-10-03 Compositions pharmaceutiques comprenant du fenofibrate et de l'atorvastatine
EP05789004A EP1804769A1 (fr) 2004-10-01 2005-10-03 Compositions pharmaceutiques comprenant du fenofibrate et de l'atorvastatine
US11/449,918 US9173847B2 (en) 2003-10-10 2006-06-09 Tablet comprising a fibrate
US11/456,566 US20070014846A1 (en) 2003-10-10 2006-07-11 Pharmaceutical compositions comprising fenofibrate and atorvastatin

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
DKPA200401506 2004-10-01
DKPA200401506 2004-10-01
DKPA200401761 2004-11-15
DKPA200401761 2004-11-15
DKPA200402004 2004-12-23
DKPA200402004 2004-12-23
DKPA200500196 2005-02-09
DKPA200500196 2005-02-09
DKPA200500534 2005-04-13
DKPA200500534 2005-04-13

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/449,918 Continuation-In-Part US9173847B2 (en) 2003-10-10 2006-06-09 Tablet comprising a fibrate

Publications (1)

Publication Number Publication Date
WO2006037344A1 true WO2006037344A1 (fr) 2006-04-13

Family

ID=35726678

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/DK2005/050001 WO2006037344A1 (fr) 2003-10-10 2005-10-03 Compositions pharmaceutiques comprenant du fenofibrate et de l'atorvastatine
PCT/DK2005/050004 WO2006037347A1 (fr) 2003-10-10 2005-10-03 Compositions pharmaceutiques contenant du fenofibrate et de l'atorvastatine

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/DK2005/050004 WO2006037347A1 (fr) 2003-10-10 2005-10-03 Compositions pharmaceutiques contenant du fenofibrate et de l'atorvastatine

Country Status (3)

Country Link
EP (2) EP1804769A1 (fr)
CA (2) CA2582405A1 (fr)
WO (2) WO2006037344A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006084474A2 (fr) * 2005-02-10 2006-08-17 Lifecycle Pharma A/S Preparation pharmaceutique stable comprenant une dose fixe de fenofibrate et d'un inhibiteur de la hmg-coa reductase
WO2008075320A2 (fr) * 2006-12-21 2008-06-26 Ranbaxy Laboratories Limited Compositions pharmaceutiques antilipidémiques et leur procédé de préparation
US7569612B1 (en) 2006-08-21 2009-08-04 Mutual Pharmaceutical Company, Inc. Methods of use of fenofibric acid
WO2009147009A2 (fr) * 2008-06-06 2009-12-10 Nicox S.A. Compositions comprenant de l'ester 4-(nitrooxy)butylique d'atorvastatine et un médicament hypolipidémique
US20110217289A1 (en) * 2010-03-05 2011-09-08 Basf Se Melt-Coated Dosage Forms
WO2011107466A3 (fr) * 2010-03-05 2011-12-15 Basf Se Formes pharmaceutiques enrobées d'une matière fondue
US20120183623A1 (en) * 2009-09-17 2012-07-19 Basf Se Pellets Coated With Coatings Containing Active Substances
WO2022071787A1 (fr) 2020-09-29 2022-04-07 Laboratorios Silanes S.A. De C.V. Combinaisons pharmaceutiques de statines et fibrates pour le traitement et la prévention d'hyperlipidémies et de maladies cardiovasculaires

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110097414A1 (en) * 2007-02-26 2011-04-28 Sandal Roshan Lal Pharmaceutical compositions comprising adsorbate of fenofibrate
WO2008117154A2 (fr) * 2007-03-26 2008-10-02 Torrent Pharmaceuticals Limited Compositions pharmaceutiques stables d'inhibiteur de hmg-coa réductase et leur procédé de préparation
CN102525942A (zh) * 2012-01-05 2012-07-04 金陵药业股份有限公司 一种阿托伐他汀钙肠溶微丸及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002024169A1 (fr) * 2000-09-20 2002-03-28 Skyepharma Canada Inc. Procede de sechage par atomisation et compositions de fenofibrate
WO2003004001A1 (fr) * 2001-07-06 2003-01-16 Lifecycle Pharma A/S Agglomeration controlee
US20030162827A1 (en) * 2002-01-30 2003-08-28 Suresh Venkataram HMG CoA reductase inhibiting composition, method of preparation thereof and method for competitively inhibiting HMG CoA reductase using such composition
WO2004073687A1 (fr) * 2003-02-19 2004-09-02 H. Lundbeck A/S Procede de preparation d'un agglomere par agglomeration a chaud
WO2005034908A2 (fr) * 2003-10-10 2005-04-21 Lifecycle Pharma A/S Forme posologique solide comprenant une fibrate et une statine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002024169A1 (fr) * 2000-09-20 2002-03-28 Skyepharma Canada Inc. Procede de sechage par atomisation et compositions de fenofibrate
WO2003004001A1 (fr) * 2001-07-06 2003-01-16 Lifecycle Pharma A/S Agglomeration controlee
US20030162827A1 (en) * 2002-01-30 2003-08-28 Suresh Venkataram HMG CoA reductase inhibiting composition, method of preparation thereof and method for competitively inhibiting HMG CoA reductase using such composition
WO2004073687A1 (fr) * 2003-02-19 2004-09-02 H. Lundbeck A/S Procede de preparation d'un agglomere par agglomeration a chaud
WO2005034908A2 (fr) * 2003-10-10 2005-04-21 Lifecycle Pharma A/S Forme posologique solide comprenant une fibrate et une statine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHEU ET AL: "Characterization and dissolution of fenofibrate solid dispersion systems", INTERNATIONAL JOURNAL OF PHARMACEUTICS, AMSTERDAM, NL, vol. 103, no. 2, 1994, pages 137 - 146, XP002091325, ISSN: 0378-5173 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006084474A2 (fr) * 2005-02-10 2006-08-17 Lifecycle Pharma A/S Preparation pharmaceutique stable comprenant une dose fixe de fenofibrate et d'un inhibiteur de la hmg-coa reductase
WO2006084474A3 (fr) * 2005-02-10 2006-11-02 Lifecycle Pharma As Preparation pharmaceutique stable comprenant une dose fixe de fenofibrate et d'un inhibiteur de la hmg-coa reductase
AU2010201739B2 (en) * 2005-02-10 2012-03-29 Veloxis Pharmaceuticals A/S A stable pharmaceutical composition comprising a fixed dose combination of fenofibrate and an HMG-CoA reductase inhibitor
US7569612B1 (en) 2006-08-21 2009-08-04 Mutual Pharmaceutical Company, Inc. Methods of use of fenofibric acid
US7741374B1 (en) 2006-08-21 2010-06-22 Mutual Pharmaceutical Company, Inc. Methods of use of fenofibric acid
US7741373B1 (en) 2006-08-21 2010-06-22 Mutual Pharmacuetical Company, Inc. Methods of use of fenofibric acid
US7915247B1 (en) 2006-08-21 2011-03-29 Mutual Pharmaceutical Company, Inc. Methods of use of fenofibric acid
WO2008075320A3 (fr) * 2006-12-21 2008-08-14 Ranbaxy Lab Ltd Compositions pharmaceutiques antilipidémiques et leur procédé de préparation
WO2008075320A2 (fr) * 2006-12-21 2008-06-26 Ranbaxy Laboratories Limited Compositions pharmaceutiques antilipidémiques et leur procédé de préparation
WO2009147009A2 (fr) * 2008-06-06 2009-12-10 Nicox S.A. Compositions comprenant de l'ester 4-(nitrooxy)butylique d'atorvastatine et un médicament hypolipidémique
WO2009147009A3 (fr) * 2008-06-06 2010-07-01 Nicox S.A. Compositions comprenant de l'ester 4-(nitrooxy)butylique d'atorvastatine et un médicament hypolipidémique
US20120183623A1 (en) * 2009-09-17 2012-07-19 Basf Se Pellets Coated With Coatings Containing Active Substances
US8951569B2 (en) * 2009-09-17 2015-02-10 Basf Se Pellets coated with coatings containing active substances
US20110217289A1 (en) * 2010-03-05 2011-09-08 Basf Se Melt-Coated Dosage Forms
WO2011107466A3 (fr) * 2010-03-05 2011-12-15 Basf Se Formes pharmaceutiques enrobées d'une matière fondue
WO2022071787A1 (fr) 2020-09-29 2022-04-07 Laboratorios Silanes S.A. De C.V. Combinaisons pharmaceutiques de statines et fibrates pour le traitement et la prévention d'hyperlipidémies et de maladies cardiovasculaires

Also Published As

Publication number Publication date
EP1804769A1 (fr) 2007-07-11
EP1804768A1 (fr) 2007-07-11
CA2582403A1 (fr) 2006-04-13
CA2582405A1 (fr) 2006-04-13
WO2006037347A1 (fr) 2006-04-13

Similar Documents

Publication Publication Date Title
US20070009603A1 (en) Compositions comprising fenofibrate and atorvastatin
WO2006037348A1 (fr) Compositions pharmaceutiques contenant du fenofibrate et une statine
US20070014846A1 (en) Pharmaceutical compositions comprising fenofibrate and atorvastatin
AU2010201739B2 (en) A stable pharmaceutical composition comprising a fixed dose combination of fenofibrate and an HMG-CoA reductase inhibitor
EP1804769A1 (fr) Compositions pharmaceutiques comprenant du fenofibrate et de l'atorvastatine
US9173847B2 (en) Tablet comprising a fibrate
JP5069001B2 (ja) フィブラートを含む固体投与形態
US20050096391A1 (en) Compositions comprising fenofibrate and rosuvastatin
US20050096390A1 (en) Compositions comprising fenofibrate and pravastatin
WO2008075320A2 (fr) Compositions pharmaceutiques antilipidémiques et leur procédé de préparation
WO2006037345A1 (fr) Compositions pharmaceutiques comprenant du fenofibrate et de la simvastatine
CN101594850A (zh) 降血脂药物组合物和及其制备方法
WO2006084475A2 (fr) Comprimé comprenant un fibrate
WO2005011642A9 (fr) Composition pharmaceutique a unite simple comprenant un melange de fibranne et un agent reducteur d'homocysteine
CN114173786A (zh) 包含hmg-辅酶a还原酶抑制剂和非诺贝特的药物组合物
AU2004279661B2 (en) A solid dosage form comprising a fibrate and a statin
KR101302306B1 (ko) 고지혈증 복합제
US20130115246A1 (en) Reduced dose oral pharmaceutical compositions of fenofibrate
US20070160663A1 (en) Single unit pharmaceutical composition comprising a mixture of fenofibrate and a modified release form of a homocysteine reducing agent
AU2003254428B2 (en) Stable controlled release pharmaceutical compositions containing Fenofibrate and Pravastatin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 11449918

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 11456566

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 11456566

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 11449918

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2582403

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005789004

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1883/CHENP/2007

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 2005789004

Country of ref document: EP